Abdel Wahab N, Mason R M
Department of Biochemistry, Charing Cross and Westminster Medical School, London, U.K.
Biochem J. 1996 Dec 15;320 ( Pt 3)(Pt 3):777-83. doi: 10.1042/bj3200777.
We report on the effect of prolonged hyperglycaemic (11 and 30 mM D-glucose) culture conditions on human mesangial cell matrix metalloproteinases (MMPs), plasminogen activators and their inhibitors. The results indicate that hyperglycaemic conditions modulate the potential proteolytic activity of the enzymes secreted by confluent cultures of these cells. Gelatinase A (MMP-2) activity was always higher in cultures maintained under hyperglycaemic than under normoglycaemic conditions (4 mM D-glucose). In contrast, gelatinase B (MMP-9) activity was decreased under the same conditions. Matrilysin (MMP-7) activity was decreased by up to 100% under hyperglycaemic conditions. Reverse transcriptase-PCR and Western-blotting analyses indicate that in all cases both the transcripts and the protein level were correlated with enzymic activity. One tissue inhibitor of metalloproteinases, TIMP-2, was barely detectable under hyperglycaemic conditions (30 mM D-glucose). In contrast, TIMP-1 increased during the initial 2 weeks of culture in hyperglycaemic conditions and remained elevated to the end of the experiment (4 weeks). Under normoglycaemic conditions TIMP-1 decreased after 2 weeks of culture. Hyperglycaemic conditions also decreased markedly the activity of tissue plasminogen activator (t-PA). This seemed to be due to increased synthesis of its inhibitor, plasminogen activator inhibitor 1, under these conditions rather than to decreased expression of the t-PA enzyme.
我们报告了长期高血糖(11和30 mM D-葡萄糖)培养条件对人系膜细胞基质金属蛋白酶(MMPs)、纤溶酶原激活剂及其抑制剂的影响。结果表明,高血糖条件可调节这些细胞汇合培养物分泌的酶的潜在蛋白水解活性。在高血糖条件下培养的细胞中,明胶酶A(MMP-2)的活性始终高于正常血糖条件(4 mM D-葡萄糖)下培养的细胞。相反,在相同条件下,明胶酶B(MMP-9)的活性降低。在高血糖条件下,基质溶素(MMP-7)的活性降低了100%。逆转录聚合酶链反应和蛋白质印迹分析表明,在所有情况下,转录本和蛋白质水平均与酶活性相关。在高血糖条件(30 mM D-葡萄糖)下,几乎检测不到一种金属蛋白酶组织抑制剂TIMP-2。相反,在高血糖条件下培养的最初2周内,TIMP-1增加,并在实验结束时(4周)保持升高。在正常血糖条件下,培养2周后TIMP-1降低。高血糖条件也显著降低了组织纤溶酶原激活剂(t-PA)的活性。这似乎是由于在这些条件下其抑制剂纤溶酶原激活剂抑制剂1的合成增加,而不是由于t-PA酶的表达降低。